A genetic register for von Hippel-Lindau disease was set up in the north west of England in 1990.
Abstract
A genetic register for von Hippel-Lindau disease was set up in the north west of England in 1990 . Population statistics, clinical features, age at onset, and survival of 83 people affected with von Hippel-Lindau (VHL) disease were studied. In addition, the effectiveness of the screening programme used and the occurrence of central nervous system haemangioblastomas in the general population were examined. The diagnostic point prevalence of heterozygotes in the North Western Region was 1 18/100 000 (1/ 85 000) people, with an estimated birth incidence of 2-20/100 000 (1/45 500) live births. The mutation rate was estimated directly to be 1*4 x 10-6/genelgeneration (1/714 200).
The mean age at onset of first symptoms was 26-25 years, with cerebellar haemangioblastomabeingthe most common presenting manifestation (34-90/o ofcases). The mean age at diagnosis of VHL disease was 30-87 years. Overall, 50 patients (60.2%) developed a cerebellar haemangioblastoma, 34 (41.0%) a retinal angioma, 21 (25.3%) a renal cell carcinoma, 12 ( The total number of heterozygotes living in the north west was then used to calculate the point prevalence of the disease (based on a total population of the NW region of 4 030 800). 18 The diagnostic prevalence underestimates the birth incidence because of the late age at presentation and early age at death. Therefore, the birth incidence for VHL disease in the NW region was calculated by determining the number of living heterozygotes aged 25 to 49 years (the age group in which ascertainment of heterozygotes is likely to be most accurate), taking into account both the known heterozygotes and those contained within the 50% prior risk group. After the addition of further subjects with VHL disease born between 30.11.1944 and 1.12.1969 but who had died before the study date, the total was divided by the total number of people in the NW region aged 25-49 years to obtain the prevalence in this age group; this figure was taken to be an estimate of the birth incidence.
In order to estimate the mutation rate, the number of new mutations (as determined by pedigree analysis) in those aged 25-49 years was divided by the population of this age group in the NW region to give the population frequency of new mutations in this age group. This was then halved to give a direct estimate of the mutation rate.
The screening programme used for all affected and at risk subjects is summarised in the appendix. All feature diagnoses made were divided by the number of screens made and any interval diagnosis was recorded.
The identification of cases of VHL disease that had not been referred to the genetic departments, and hence were not included on the VHL disease register, was attempted using the North West Cancer Registry. A listing was produced of all central nervous system HBs registered between 1971 and 1993. The list of cases was matched against the VHL register. Efforts were made to identify patients with retinal angioma by searching patient records at the local regional ophthalmological referral centre. The registry database was searched for the occurrence of a second primary neoplasm in the people with CNS HBs. Hospital notes were requested for those people in whom a second primary neoplasm had been diagnosed, and also for patients who were 35 years of age or younger at the time of diagnosis of the HB. The information obtained from the cancer registry was also used to estimate the percentage of all CNS HBs that occur as part of on the study day. The 49 subjects alive in the NW region who had a prior risk of 50%, when analysed using the age related risk curve, showed that there were likely to be 17-6 heterozygotes among them. The number of isolated cases aged 25-49 years was found to be four (including two isolated cases born between 1.12.1944 and 30.11.1969 who had died before the study day), and from this it was estimated that there were 3 8 isolated heterozygotes under the age of 25 years in the NW region who have not yet been diagnosed.
Therefore, the total number of heterozygotes for VHL disease in the NW region was estimated to be 47*4, giving a minimum heterozygote prevalence of 1 -18 per 100 000 or 1 per 85 000 people.
BIRTH INCIDENCE
The number of affected subjects who were between the ages of 25 and 49 years and who were living in the NW region was found to be 17. There were also 26 subjects in the same age group and living in the NW region who were at a 50% prior risk of carrying the VHL disease gene; analysis using the age related risk curve showed that there were likely to be 4.4 heterozygotes among them. In addition, there were 10 affected subjects who were born between 1.12.1944 and 30.11.1969 but who had died before the study day. Therefore, the total number of heterozygotes for VHL disease in the 25-49 year age group was estimated to be 31 4, giving a minimum birth incidence (which was taken to be the prevalence in this age group) of 2-20 per 100 000 or 1 shown not to carry the gene defect. One of the families in which a VHL mutation was not identified has a suitable structure for linkage analysis and informative testing is in progress. Only two subjects have positively declined predictive testing, one at 50% risk and the other being the brother of a presumed new mutation; both have partaken in clinical and radiological screening. It is anticipated that the majority of people undergoing active screening will undertake predictive testing.
AGE AT DEATH OF VHL PATIENTS
Of the 83 affected subjects, 44 had died by the study day, and information regarding age at death was available for 39 of these. Mean age at death in VHL patients was found to be 409 (SD= 14-57, range=12-65) years (n=39 The possibility of VHL was mentioned in only 4/21 cases: once in the pathology report, once by a referring physician, and only twice by the treating neurosurgeon. In the latter two cases limited further investigations were undertaken. In a number of other cases VHL appeared to have been considered because of the investigations carried out. Several cases had been referred for ophthalmic examination and one had had a normal abdominal ultrasound scan. Three asymptomatic sibs of one case had brain scans though the affected subject did not have any further investigation.
Discussion POPULATION STATISTICS
Since VHL disease was identified as a distinct disease entity in 1926, there have been more than 700 cases reported in English language publications.23 To the best estimate of the various ascertainment methods used the diagnostic prevalence of heterozygotes for VHL disease in the NW region (1/85 000 people) is of the same order of magnitude as that estimated in previous reports, but when compared with some recent reports,'7 '9 it is considerably lower, although Maher et al'7 concede that their estimate of the point prevalence in East Anglia (1/53 000 people) is somewhat higher than in other reports. The birth incidence of VHL disease (1/45 500 live births), although also being a little lower than the one estimated by Maher et al,'7 is very similar to the one calculated by Harries.9 FIRST MANIFESTATION OF VHL DISEASE CHB was the most common presenting manifestation of VHL disease, with RA (which is regarded by most as being the earliest manifestation of VHL disease)3 being the second most common in our series. However, the mean ages at onset and at diagnosis of RA when it was the presenting complication were considerably lower than those of CHB. Mean ages at onset overall and for each of the four most common presenting manifestations were similar to those found in other similar studies.23 However, we found that on average the diagnosis of VHL disease was made over four and a half years after the onset of symptoms. Again, screening and higher awareness of the disease may help to reduce this delay. Although most subjects show features of VHL disease relatively early on in life, the diagnosis of the disease was made in 12 people who were over the age of 50 Once the VHL register has been longer established, it is likely that the majority of lesions will be detected asymptomatically. The rates of detection of asymptomatic lesions (table 5) also show that the highest detection rates are found in those lesions that often remain asymptomatic: CHB, pancreatic cysts, and renal cysts. The occurrence of a CHB and a pancreatic carcinoma as interval tumours shows that the sensitivity ofthe screening tests is not 100%, but this is to be expected since the attainment of 100% sensitivity would mean overinvestigation in the majority of cases. However, the use of MR scanning in place of CT scanning may reduce the number of lesions that pass undetected. DNA TESTING In our series, DNA linkage analysis and direct mutation testing proved useful in confirming the diagnosis of VHL disease in six families and in substantially reducing the probability of carrying the VHL disease gene in a further 18 subjects; in the latter it was considered appropriate to relax the screening programme. In future years, with improved techniques of identification of mutations, it will hopefully be possible to offer predictive testing to the great majority of at risk people. Although screening using radiological and genetic tests may reduce the morbidity and mortality associated with VHL disease, it must be remembered that long term compliance with the complicated screening protocol may be difficult to achieve. Nonetheless, gene testing will concentrate screening on those really at risk and the resources saved on unaffected subjects may allow more rigorous screening of the gene carriers.
DEATH FROM VHL DISEASE
The mean age at death was similar to that found in other studies.23 The majority of previous reports have found CHB to be the most frequent cause of death in VHL disease patients,20 and this was also the case in our study. However, one must also take into account that nearly two and a half times as many people were diagnosed with a CHB than were diagnosed with a RCC, and hence RCC (when present) was the lesion with the highest mortality. This is further substantiated by the values for survival following treatment, which show that the lowest duration of survival was found following nephrectomy for RCC.
OBLIGATE CARRIERS OF THE VHL DISEASE GENE
Three subjects remained asymptomatic in spite of having both affected sibs and children, and were hence identified as being obligate carriers of the VHL disease gene.2' Two of these are alive and aged 53 years and 67 years, while the third died of pneumonia in 1990 at the age of 50 years. The 67 year old subject has previously been reported,'8 and was only recently found after careful screening to have bilateral renal cysts. Although commonly found as part of VHL disease (with one study reporting that they occur in more than two thirds of VHL patients),9 renal cysts are also a common finding in the general population. One series found that 27% of the general population over the age of 50 
